• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Iteos HomeIteos HomeIteos Home

Scientific Advisory Board

  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
    • Corporate Responsibility
  • Pipeline
    • Our Pipeline
    • Clinical Trials
    • A2A Receptor Antagonist
    • Anti-TIGITmAb FcyR-Engaging
  • Investors
    • Investors Overview
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Technology
  • Careers
  • Contact

Explore

  • Clinical Trials
  • Inupadenant
  • EOS-448
  • Scientific Publications
  • Our Science
  • Presentations
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
    • Corporate Responsibility
  • Pipeline
    • Our Pipeline
    • Clinical Trials
    • A2A Receptor Antagonist
    • Anti-TIGITmAb FcyR-Engaging
  • Investors
    • Investors Overview
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Technology
  • Careers
  • Contact

Explore

  • •Clinical Trials
  • •Inupadenant
  • •EOS-448
  • •Scientific Publications
  • •Our Science
  • •Corporate Presentations
  • Pipeline

    Review our development pipeline, clinical trials, and other innovations.

  • Press

    Explore our latest company news, press releases, and events.

  • Careers

    Discover more about our company culture and explore current openings.

  • ESG

    Review our Environmental, Social and Governance guidelines.

Home / About Us / Scientific Advisory Board

We have assembled a group of experts in immuno-oncology who advise us in our research and development activities.

iTeos’ Scientific Advisory Board board provides an external scientific review of R&D activities and assists us in making significant scientific judgments related to R&D activities and portfolio management and prioritization.

Our teams

Meet our management team
Meet our Board of Directors
Get information on partnering
Explore our ESG

Scientific Advisory Board

Florent GINHOUX, Ph.D.

Valerie ODEGARD, Ph.D.

Roberta ZAPPASODI, Ph.D.

Gordon FREEMAN, Ph.D.

Benoît VAN DEN EYNDE, M.D., Ph.D.

Matthew VANDER HEIDEN, M.D., Ph.D.

We work together to develop breakthrough therapies to treat cancer through improving the immune response.

Management team

Our leadership team combine biotech and pharma expertise in immuno-oncology, clinical and corporate strategy to manage the activities of iTeos both in Europe and USA in order to develop and deliver the next generation of cancer immunotherapies.

Meet our management team

Board of Directors

We have built a Board composed of the different talents to support the growth and differentiation of iTeos as a leader in development of the next generation of cancer immunotherapies by combining expertise in immuno-oncology, clinical strategy, company builders, corporate strategy, finance and commercialization.

Meet our Board of Directors

Footer

Cancer immunotherapies
by designTM

iTeos US

321 Arsenal St
Bldg 312, Suite 301
Watertown, MA 02472
United States

iTeos Belgium

Rue des Frères Wright 29
6041 Gosselies
Belgium

  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
    • Corporate Responsibility
  • Pipeline
    • Our Pipeline
    • Clinical Trials
    • A2A Receptor Antagonist
    • Anti-TIGITmAb FcyR-Engaging
  • Investors
    • Investors Overview
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Technology
  • Careers
  • Contact
Iteos Logo

© 2022 iTeos Therapeutics. iTeos, iTeos logo and Cancer Immunotherapies By Design are trademarks of iTeos Therapeutics Inc.

Privacy Policy   |   Terms of Use

  • Twitter
  • LinkedIn
Manage Cookie Consent
This website needs some cookies and similar means to function. If you permit us, we will use those means to collect data on your visits for aggregated statistics.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}